Edodekin alfa
Also known as: Edodekin-alfa, IL-13 mutein, IL-13-PE38QQR (related conjugate), recombinant human IL-13 mutein
Source Edodekin alfa at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Edodekin alfa is an investigational recombinant human interleukin‑13 (IL‑13) mutein being explored for therapeutic use. It is classified as an IL‑13 antagonist cytokine and is listed in clinical trial databases, but no published trial outcomes are available. The compound is administered locally via convection‑enhanced delivery, intralesional or intratumoral injection.
Mechanism of Action
Edodekin alfa is a recombinant human IL‑13 mutein designed to bind IL‑13 receptors and competitively inhibit native IL‑13 signaling. By blocking IL‑13–mediated activation of downstream pathways such as STAT6, the molecule is intended to modulate immune and inflammatory responses that are driven by IL‑13. The exact binding affinity and downstream effects have not been detailed in the cited literature.
What the Research Shows
The only peer‑reviewed references that mention edodekin alfa are a series of “Gateways to Clinical Trials” listings (2003‑2005) that catalog the compound among many others in clinical development databases. These entries confirm that edodekin alfa has been recognized as an investigational agent and note its inclusion in trial registries, but they do not provide data on study design, patient populations, efficacy outcomes, or safety observations. A USAN Council note (1999) records the assignment of the non‑proprietary name. Consequently, the published evidence for edodekin alfa is limited to its identification as a candidate drug rather than any reported clinical results.
Reported Benefits
Potential benefits of edodekin alfa are inferred from its role as an IL‑13 antagonist, which could theoretically attenuate IL‑13‑driven pathological processes such as tumor growth or inflammatory disease. However, no clinical or pre‑clinical studies have been published that demonstrate actual therapeutic advantage, so any benefit remains speculative pending formal investigation.
Limitations of the Evidence
Evidence for edodekin alfa is confined to database listings without accompanying efficacy or safety data, representing a major gap in knowledge. No peer‑reviewed trials, pharmacokinetic profiles, or dose‑response information are available. The lack of published results makes it impossible to assess therapeutic value or compare it with existing IL‑13 targeting agents.
Safety Considerations
Safety information for edodekin alfa is not reported in the available abstracts. Without published pre‑clinical or clinical safety assessments, potential adverse effects, tolerability, or contraindications are unknown. Researchers should treat the compound as experimental and monitor for typical cytokine‑related toxicities in any future studies.
How It Is Administered
Edodekin alfa is described for local delivery methods, including convection‑enhanced delivery, intralesional injection, and intratumoral injection. Formulation details such as concentration or vehicle are not provided in the cited literature.
Routes of Administration
Goals & Uses
- Treatment of recurrent glioblastoma multiformeOncologyModerate
- Blockade of IL-13 pro-tumorigenic signalingOncology / ImmunologyModerate
- Treatment of atopic dermatitisImmunology / DermatologyLow
Contraindications
- Hypersensitivity to IL-13 mutein or excipientsAllergyHigh
- Coagulopathy or hemorrhagic diathesisHematologyHigh
- Active intracranial infectionInfectionHigh
Adverse Effects
- HeadacheNeurologicCommonPain in the head or upper neck
- Neurological deteriorationNeurologicalUncommon
- Fever / flu-like symptomsSystemicUncommon
- SeizuresNeurologicalUncommon
- Peritumoral edemaNeurologicalCommon
Drug Interactions
- CorticosteroidsLow
Population Constraints
- Pediatric patientsAgeRelative
- Pregnant womenReproductiveRelative
- Patients with poor performance statusClinicalRelative
Regulatory Status
- European UnionUnknownNo known EMA approval or marketing authorization.
- United StatesInvestigationalFDA Orphan Drug Designation granted for malignant glioma; no approved indication. Studied in phase I/II trials.
- United KingdomUnknownNo known MHRA approval or marketing authorization.
Edodekin alfa has been studied in clinical trials for recurrent glioblastoma multiforme under FDA investigational status. It has received no marketing approval in any major jurisdiction. Orphan Drug Designation was granted by the FDA for malignant glioma.
Evidence & Sources
- Journal ArticleLowBayés M, Rabasseda X, Prous JR2003-01-01T00:00:00.000000Z
- Journal ArticleModerateBayes M, Rabasseda X, Prous JR2004-01-01T00:00:00.000000Z
- Journal ArticleLowBayes M2007-01-01T00:00:00.000000Z
- Journal ArticleLowBayes M, Rabasseda X, Prous JR2003-01-01T00:00:00.000000Z
- Journal ArticleLowBayés M, Rabasseda X, Prous JR2005-01-01T00:00:00.000000Z
- Journal ArticleLow1999-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of molecule is edodekin alfa?
Edodekin alfa is a recombinant human interleukin‑13 mutein designed to act as an antagonist of IL‑13 signaling. It belongs to the interleukin family and is classified as an investigational cytokine.
Has edodekin alfa been tested in humans?
The compound appears in clinical trial registries, indicating that human studies may have been planned or initiated, but no published trial results or data are available to confirm completed human testing.
How is edodekin alfa administered?
Reported routes of administration are local injections: convection‑enhanced delivery, intralesional, and intratumoral injection. No systemic delivery routes are mentioned in the literature.
What is known about its safety profile?
No safety data have been published. Potential adverse effects are unknown, and the compound should be considered experimental until formal safety assessments are reported.
What therapeutic areas might edodekin alfa target?
As an IL‑13 antagonist, it could theoretically be explored for diseases where IL‑13 contributes to pathology, such as certain cancers or inflammatory conditions, but no specific indications have been demonstrated in the literature.
What is Edodekin alfa used for?
Edodekin alfa is educationally associated with: Treatment of recurrent glioblastoma multiforme, Blockade of IL-13 pro-tumorigenic signaling, Treatment of atopic dermatitis. Educational only — not medical advice.
How is Edodekin alfa administered?
Recorded routes of administration: Convection Enhanced Delivery, Intralesional, Intratumoral.
What are the potential side effects of Edodekin alfa?
Reported adverse effects include: Headache, Neurological deterioration, Fever / flu-like symptoms, Seizures, Peritumoral edema. This list is not exhaustive — consult a qualified clinician.
Who should avoid Edodekin alfa?
Recorded contraindications: Hypersensitivity to IL-13 mutein or excipients, Coagulopathy or hemorrhagic diathesis, Active intracranial infection. Consult a qualified clinician before use.